Suppr超能文献

相似文献

1
Novel CYP2C9 promoter variants and assessment of their impact on gene expression.
Mol Pharmacol. 2008 Jun;73(6):1751-60. doi: 10.1124/mol.107.044149. Epub 2008 Feb 29.
3
CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.
Clin Pharmacol Ther. 2005 May;77(5):353-64. doi: 10.1016/j.clpt.2005.01.019.
4
A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.
Br J Clin Pharmacol. 2010 Aug;70(2):213-21. doi: 10.1111/j.1365-2125.2010.03688.x.
6
Global variation in CYP2C8-CYP2C9 functional haplotypes.
Pharmacogenomics J. 2009 Aug;9(4):283-90. doi: 10.1038/tpj.2009.10. Epub 2009 Apr 21.
7
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. doi: 10.1124/jpet.109.161026. Epub 2009 Oct 23.
8
Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.
J Pharmacol Exp Ther. 2004 Feb;308(2):495-501. doi: 10.1124/jpet.103.058818. Epub 2003 Nov 4.
9
Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards.
Pharmacogenomics J. 2004;4(6):403-6. doi: 10.1038/sj.tpj.6500278.
10
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Pharmacogenet Genomics. 2006 Jul;16(7):497-514. doi: 10.1097/01.fpc.0000215069.14095.c6.

引用本文的文献

1
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
BMC Genomics. 2025 Feb 13;26(1):140. doi: 10.1186/s12864-025-11310-9.
4
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
J Pers Med. 2017 Dec 28;8(1):1. doi: 10.3390/jpm8010001.
5
Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.
Appl Transl Genom. 2013 Aug 27;3(1):8-13. doi: 10.1016/j.atg.2013.07.002. eCollection 2014 Mar 1.
6
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.
Drug Metab Pers Ther. 2015 Jun;30(2):87-105. doi: 10.1515/dmdi-2014-0023.
7
CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
Drug Metab Dispos. 2012 May;40(5):884-91. doi: 10.1124/dmd.111.044255. Epub 2012 Jan 30.
8
Cytochrome P450 2C9-CYP2C9.
Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84.
9
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. doi: 10.1124/jpet.109.161026. Epub 2009 Oct 23.
10
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045. Epub 2009 Feb 21.

本文引用的文献

1
Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver.
Drug Metab Dispos. 2006 Jun;34(6):1012-8. doi: 10.1124/dmd.106.009365. Epub 2006 Mar 15.
2
Strong bias in the location of functional promoter polymorphisms.
Hum Mutat. 2005 Sep;26(3):214-23. doi: 10.1002/humu.20207.
4
CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.
Clin Pharmacol Ther. 2005 May;77(5):353-64. doi: 10.1016/j.clpt.2005.01.019.
6
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
Pharmacogenetics. 2004 Dec;14(12):813-22. doi: 10.1097/00008571-200412000-00004.
7
Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards.
Pharmacogenomics J. 2004;4(6):403-6. doi: 10.1038/sj.tpj.6500278.
9
Discovery of new potentially defective alleles of human CYP2C9.
Pharmacogenetics. 2004 Aug;14(8):527-37. doi: 10.1097/01.fpc.0000114759.08559.51.
10
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Drug Metab Dispos. 2004 May;32(5):484-9. doi: 10.1124/dmd.32.5.484.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验